For 42 (38%) of the drugs, there was wide consistency in PDL design, with at least 9 states classifying the drug with the same PDL status. For the other 62% of drugs, there was greater variation, with 2 or more states classifying the drugs differently than the others. Generosity and consistency also varied by therapeutic […]
The objective of this analysis is to simulate the difference between national and state-specific individual insurance markets on take-up of individual health insurance. First, we reviewed the literature to characterize the state-specific individual insurance markets with respect to state regulations and to identify the effect of those regulations on health insurance premiums. Second, we used […]
The average in-lab cost per coronary stent patient increased from $3,338 in the fourth quarter of 2001 to $4,644 in the fourth quarter of 2006, and spending on devices and drugs accounted for 98 percent of the increase. Read the full paper at HealthAffairs.org here.
This technical report was produced for the Office of the Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services. The report extends and refines prior research on consumer directed health plans by incorporating the effect of prior health status on health plan choice – a necessary step for predicting health […]
This paper estimated the effects of tort law and insurer investment returns on physician malpractice insurance premiums. Data were collected on tort law from 1991 through 2004, and multivariate regression models, including fixed effects for state and year, were used to estimate the effect of changes in tort law on medical malpractice premiums. Read the […]